LENZ Therapeutics (LENZ) Total Liabilities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Total Liabilities data on file, last reported at $26.0 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 181.79% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was $26.0 million, a 181.79% increase from a year earlier, with the FY2025 full-year figure at $21.5 million, up 91.95% from the prior year.
• Total Liabilities for Q1 2026 stood at $26.0 million, up from $21.5 million in the prior quarter.
• Over the last five years, Total Liabilities for LENZ reached as high as $62.9 million in Q2 2023 and fell as low as $8.7 million in Q3 2024.
• Historically, Total Liabilities has averaged $22.9 million across 5 years, with a median of $18.4 million in 2022.
• Across the five-year window, Total Liabilities jumped 310.29% in 2023 and tumbled 85.97% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $25.6 million in 2022, then dropped by 23.09% to $19.7 million in 2023, then sank by 43.04% to $11.2 million in 2024, then soared by 91.95% to $21.5 million in 2025, then advanced by 20.92% to $26.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $26.0 million in Q1 2026, $21.5 million in Q4 2025, and $16.8 million in Q3 2025.